ArticleBriefings in bioinformatics2023
Development of innovative multi-epitope mRNA vaccine against Pseudomonas aeruginosa using in silico approaches.
Article in Briefings in bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Bacterial mRNA Vaccines: Programming Immunity Against Antimicrobial Resistance.Drug development research · 2026Review
- Design of a novel proteome-derived scaffold presenting epitopes of Pseudomonas aeruginosa in native conformation.Scientific reports · 2026Article
- Taming Superbugs: Current Progress and Challenges in Combating ESKAPE Pathogens.Pathogens (Basel, Switzerland) · 2025Review
- In silico design and characterization of a novel multi-epitope mRNA vaccine candidate against Streptococcus pneumoniae.Scientific reports · 2025Article
- X-Ray Irradiation of Pseudomonas aeruginosa Induces Biogenesis of Outer-Inner Membrane Vesicles With Potential as a Vaccine Against Acute Pneumonia.Journal of extracellular vesicles · 2025Article
- mRNA vaccine design using the proteome ofmSphere · 2025Article
- Designing a multi-epitope vaccine against Pseudomonas aeruginosa via integrating reverse vaccinology with immunoinformatics approaches.Scientific reports · 2025Article
- Epitope-Based Vaccines: The Next Generation of Promising Vaccines Against Bacterial Infection.Vaccines · 2025Review
- Computational epitope profiling and AI-driven protein engineering enable rational design of multi-epitope vaccines againstComputational and structural biotechnology journal · 2025Article
- Development of a Novel mRNA Vaccine AgainstBioinformatics and biology insights · 2025Article
- Design of Innovative Divalent Cj1621 and CjaA Multiepitope mRNA-Based Vaccine Against FoodborneVeterinary medicine international · 2025Article
- Epitope-driven vaccine design againstIn silico pharmacology · 2025Article
- Current Progress in the Development of mRNA Vaccines Against Bacterial Infections.International journal of molecular sciences · 2024Review
- T-Cell Epitope-Based Vaccines: A Promising Strategy for Prevention of Infectious Diseases.Vaccines · 2024Review
- Antibiotic Resistance in the Elderly: Mechanisms, Risk Factors, and Solutions.Microorganisms · 2024Review
- A novel mRNA multi-epitope vaccine of Acinetobacter baumannii based on multi-target protein design in immunoinformatic approach.BMC genomics · 2024Article
- Proteomics Exploration ofBioinformatics and biology insights · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
The rising issue of antibiotic resistance has made treating Pseudomonas aeruginosa infections increasingly challenging. Therefore, vaccines have emerged as a viable alternative to antibiotics for preventing P. aeruginosa infections in susceptible individuals. With its superior accuracy, high efficiency in stimulating cellular and humoral immune responses, and low cost, mRNA vaccine technology is quickly replacing traditional methods. This study aimed to design a novel mRNA vaccine by using in silico approaches against P. aeruginosa. The research team identified five surface and antigenic proteins and selected their appropriate epitopes with immunoinformatic tools. These epitopes were then examined for toxicity, allergenicity and homology. The researchers also checked their presentation and identification by major histocompatibility complex cells and other immune cells through valuable tools like molecular docking. They subsequently modeled a multi-epitope protein and optimized it. The mRNA was analyzed in terms of structure and stability, after which the immune system's response against the new vaccine was simulated. The results indicated that the designed mRNA construct could be an effective and promising vaccine that requires laboratory and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.